September 23, 2019 | Vensana in the News

New Minnesota-based fund has $225 million to invest in young med-tech companies

21

Novel FDA PMA & de novo 510k approvals

60

U.S. Commercial Product Launches

39

Level I Clinical Trials

31

Strategic Financings

31

Exits by IPO or M&A